SavedAdd your journal

Journals / Üroonkoloji Bülteni / 2018 / Cilt: 17 - Sayı: 1

Evaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidity

Komorbiditesi Yüksek Benign Prostat Hipertrofisi Olan Hastalarda Prostat Arter Embolizasyon Etkinliğinin Değerlendirilmesi

İsmail Okan YILDIRIM
Enes DUMAN
ALİ FIRAT
Hüseyin ÇELİK
KAYA SARAÇ
Pages
41–44
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After the procedure, 2 patients experienced transient hematuria which did not require bladder irrigation, 1 patient had acute urinary retention due to dysuria, and 1 patient had transient hematospermia.Conclusion: PAE may be an alternative treatment method in BPH patients with high comorbidity

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to evaluate efficacy outcomes following prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) patients with high comorbidity.Materials and Methods: This retrospective study included 22 patients treated with PAE from May 2015 to June 2017.
📊
Key Findings & Data:Patients with Charlson comorbidity index ≥2, International Prostate Symptom Score (IPSS) >12, prostate specific antigen (PSA) levels 90 cm3 were included.
💡
Conclusion & Impact:After the procedure, 2 patients experienced transient hematuria which did not require bladder irrigation, 1 patient had acute urinary retention due to dysuria, and 1 patient had transient hematospermia.Conclusion: PAE may be an alternative treatment method in BPH patients with high comorbidity
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The purpose of this study was to evaluate efficacy outcomes following prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) patients with high comorbidity.Materials and Methods: This retrospective study included 22 patients treated with PAE from May 2015 to June 2017. Patients with Charlson comorbidity index ≥2, International Prostate Symptom Score (IPSS) >12, prostate specific antigen (PSA) levels 90 cm3 were included. Total PSA, maximum flow rate (Qmax), TPV, IPSS, post-voiding residual (PVR) values were recorded in all patients in the urology clinic before PAE and at 3 and 6 months after PAE.Results: The average patient age was 73.86±6.25 years and operative time was 80 minutes (range, 60-120 min). Pre-PAE and 6-month postPAE values were: IPSS: 25.18±6.75 and 11.27±3.29 (p<0.05), Qmax: 8.31±3.12 and 17.22±3.23 (p<0.05), PVR: 87.9±19.25 and 25.86±7.72 (p<0.05), TPV: 134.45±57.56 and 86±15.4 (p<0.05), and PSA: 3.89±1.26 and 2.11±1.06 (p<0.05). Embolization was performed unilaterally due to atherosclerosis and strictures in the internal iliac artery branches in 2 patients. After the procedure, 2 patients experienced transient hematuria which did not require bladder irrigation, 1 patient had acute urinary retention due to dysuria, and 1 patient had transient hematospermia.Conclusion: PAE may be an alternative treatment method in BPH patients with high comorbidity

Özet

Amaç: Bu çalışmanın amacı komorbitesi yüksek, benign prostat hipertrofisi (BPH) olan hastalarda prostat arter embolizasyonun (PAE) etkinliğini değerlendirmektir. Gereç ve Yöntem: Mayıs 2015-Haziran 2017 yılları arasında 22 hastada PAE yapıldı ve sonuçlar retrospektif olarak incelendi. Çalışmaya Charlson komorbidite indeksi >=2, Uluslararası Prostat Semptom Skoru (IPSS) >12, prostat spesifik antijen (PSA) 90 cm3 olan hastalar dahil edildi. Tüm hastalarda PAE öncesi ve PAE sonrası 3. ve 6. aylarda total PSA, maksimum akım hızı (Qmax), TPV, IPSS, post voiding rezidü (PVR) değerleri kaydedildi. Bulgular: Hastaların yaş ortalaması 73,86±6,25 yıl idi. Ortalama işlem süresi 80 (60-120 arasında) dakika idi. PAE öncesi ve 6. ayda total IPSS sırasıyla 25,18±6,75 ve 11,27±3,29 (p<0,05), Qmax; 8,31±3,12 ve 17,22±3,23 (p<0,05), PVR: 87,9±19,25 ve 25,86±7,72 (p<0,05), TPV: 134,45±57,56 ve 86±15,4 (p<0,05) PSA: 3,89±1,26 ve 2,11±1,06 (p<0,05) olup PAE öncesi ve 6. aydaki değerler arasında istatistiksel olarak anlamlı fark tespit edildi. İki hastada internal iliak arterdeki yaygın ateroskleroz ve darlıklar nedeniyle embolizasyon tek taraflı gerçekleştirildi. İşlem sonrası 2 hastada mesane irrigasyonu gerektirmeyen geçici hematüri, 1 hastada geçici hematospermi, 1 hastada ise dizüriye sekonder akut üriner retansiyon izlendi. Sonuç: PAE, komorbiditesi yüksek BPH hastalarında, alternatif bir tedavi yöntemi olabilir.

🔖

Cite This Article

YILDIRIM, İ. O., DUMAN, E., FIRAT, A., ÇELİK, H., SARAÇ, K. (2018). Evaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidity. Üroonkoloji Bülteni, Cilt: 17 - Sayı: 1, 41–44. https://ajindex.com/articles/334435

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479
  2. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140
  3. Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, et al. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol 2013;24:535-542
  4. Pisco JM, Pinheiro LC, Bilhim T, et al. Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 2011;22:11-19 5. Gao YA, Huang Y, Zhang R, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostateea prospective, randomized, and controlled clinical trial. Radiology 2014;270:920-928
  5. Wang MQ, Guo LP, Zhang GD, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large ([80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol 2015;15:33
  6. Bagla S, Martin CP, van Breda A, et al. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2014;25:47-52
  7. Pisco JM, Rio Tinto H, Campos Pinheiro L, et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of shortand mid-term follow-up. Eur Radiol 2013;23:2561-2572
  8. Carnevale FC, Iscaife A, Yoshinaga EM, et al. Transurethral resection of the prostate TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamiccontrolled analysis. Cardiovasc Intervent Radiol 2016;39:44-52
  9. Russo GI, Kurbatov D, Sansalone S, et al. Prostatic arterial embolization vs open prostatectomy: a 1-year matched-pair analysis of functional outcomes and morbidities. Urology 2015;86:343-348
  10. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol 2006;50:969-979.